LogicInk Genetic Signal for COVID-19

— To be announced
Unit price per

Non-invasive, saliva-based colorimetric biosensor for the early detection of COVID-19, including new variants

Think of every household in the world having a small box of LogicInk signals — similar to a box of bandaids.

LogicInk Signals can be sent in advance, and be used easily whenever and as frequently as needed, effectively giving us a shot at the detection of a disease vector as soon as it manifests — for both COVID-19 and the next pandemics to come.

Complementary to the vaccine, LogicInk Signals enable frequent testing and make sure each and every member of any group to stay healthy.

A Signal against the asymptomatic and pre-symptomatic spread of COVID-19

Making the invisible visible

We can't effectively solve for what we cannot sense. Countries shut down as the brute force approach for COVID-19 defense, producing dire consequences to our quality of life and functioning of our economies.

With LogicInk's viral RNA Signals, we make the invisible visible, allowing safe reopening of economies for everyone – businesses, employees, and customers.

A Signal that enables safe businesses

Through scalable, fast, and reliable COVID-19 test, LogicInk's viral RNA Signals enables our B2B partners let their customers and employees safely come back to their business – hotels, stadiums, large and small social spaces, offices, etc.

Building a scalable, fast, and reliable COVID-19 Signal for the entire human population

Reach out to us for partnerships →

A Signal that entire populations understand
Leveraging its patent-pending well-being sensor platform, LogicInk’s new Signal would allow for entire populations to self-administer and interpret results to screen the presence of SARS-CoV-2 RNA (COVID-19) simply by identifying an appropriate color combination.

Presymptomatic and asymptomatic detection
LogicInk Signals focus on signaling early detection, which has been shown to stem the outbreak and transmission of all viruses, including SARS-CoV-2 (COVID-19). Evidence from the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) suggests that COVID-19 can be detected in carriers 1-3 days before their symptoms appear. Presymptomatic and asymptomatic carriers can also unknowingly transmit the virus, making the need for ubiquitous, easily accessible testing critically important. 

Easy to mass-produce and mass-distribute: affordable, repeatable test
The test will be repeated as many times as needed, without interaction with medical personnel. Because LogicInk Signals can be efficiently mass-produced and are easy to apply, and do not require any testing cartridges or other complex devices, it is financially and logistically feasible to test entire populations for COVID-19. The sensitivity  of the test is designed to be comparable to the benchmark standard solutions without requiring a centralized laboratory or expert users to be involved.  All this is enabling the safe reopening of our economies.

Complementary to the vaccine
Vaccinations go hand-in-hand with frequent testing, in order to create a more resilient society against infectious diseases. LogicInk Genetic Signals are very easy to apply and read; and designed to be a highly scalable well-being sensor platform that will be able to detect a range of conditions beyond SARS-CoV-2, including new diseases or even the common flu, making sure everyone in your family or broader community stays healthy.

LogicInk Team

We’re an energetic group of people – chemists, designers, computer scientists,  synthetic biologists, physicians, social media experts, filmmakers, and architects – dedicated to the future of health-awareness and body-based self-expression.

Learn more about us →

LogicInk's investors include Village Global, the venture firm backed by some of the world’s most successful entrepreneurs such as Bill Gates, Jeff Bezos, and Mark Zuckerberg; West Ventures, market and brand experts with investor discipline; Breakout Labs, a fund within the Thiel Foundation, Metaplanet, and Atypical Ventures.

Along with Berkeley Catalyst Fund, Krillion Ventures, Mission Bay Capital, Kendall Ventures, Cloudstone Venture Capital, Marta Bulaich, Elizabeth Weil, Yoshihiro Takasawa, Richard Golob, Peter Yared, Antoine Blondeau, John Zhang, Anatoly Tikhman, James Christopherson, Jeanne Beachman, Tom Chavez, Eric Lowitt, and two Fortune 50 officers.